South Carolina is currently home to 1165 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Columbia and Spartanburg. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: Medical University of South Carolina University Hospital, Charleston, South Carolina
Conditions: Intracerebral Hemorrhage
Register for Updates
Prospective Registry of Patients Undergoing Cardiac CT With NAEOTOM Alpha PCD-CT Before TAVI Procedure
NCT07016477
Recruiting
The clinical and demographic characteristics of patients undergoing transcatheter aortic valve implantation (TAVI) pose unique challenges for coronary computed tomography (CT) imaging, as this patient population is mainly composed of elderly, frail individuals with severe aortic stenosis, multiple comorbidities, high prevalence of heavily calcified coronary artery disease (CAD) and revascularized coronary arteries. Such vulnerable patients could benefit from a more precise assessment and charact... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Coronary Artery Disease, Aortic Valve Stenosis, Tomography, X-Ray Computed
Register for Updates
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
NCT06501625
Recruiting
The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in participants with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. The study will begin with a safety lead-in phase (Phase 1b study) to determine the recommended combination dose (RDC) and then will transition to an expansion phase (Phase 2 study) to assess the clinical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Gibbs Cancer Center, Spartanburg, South Carolina
Conditions: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Charleston, South Carolina
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Register for Updates
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339
Recruiting
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: TMA Headlands LLC /ID# 259800, Myrtle Beach, South Carolina
Conditions: Hypothyroidism
Register for Updates
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807
Recruiting
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: MUSC, Charleston, South Carolina
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease
Register for Updates
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/04/2025
Locations: Charleston Neuroscience Institute (RCA Network Site), Ladson, South Carolina
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2025
Locations: Levine Cancer Institute-Rock Hill, Rock Hill, South Carolina
Conditions: Breast Cancer
Register for Updates
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
Recruiting
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/04/2025
Locations: GSK Investigational Site, Charleston, South Carolina
Conditions: Asthma
Register for Updates
Neural Bases of Vocal Sensorimotor Impairment in Aphasia
NCT04742894
Recruiting
Aphasia is the most common type of post-stroke communication disorder characterized by deficits in speech comprehension, production and control. While recovery can be promoted with speech therapy, improvement remains modest and typically requires a large number of sessions contributing to rising health care costs. Traditional aphasia therapy focus on enhancing speech motor output; however, recent evidence suggests that the auditory feedback also plays a critical role in fluent speech. Therefore,... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
06/04/2025
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Aphasia
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Velocity Clinical Research - Anderson, Anderson, South Carolina
Conditions: SARS-CoV2, COVID-19
Register for Updates